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Objective: This study was aimed to investigate endometrial histology and to find predictable clinical factors for endometrial disease (hyperpla-
sia or cancer) in women with polycystic ovary syndrome (PCOS). 
Methods: We investigated the endometrial histology and analyzed the relationship between endometrial histology and clinical parameters, 
such as LH, FSH, estradiol, testosterone, fasting and 2 hours postprandial glucose and insulin, insulin resistance, body mass index, endometrial 
thickness, menstrual status from 117 women with PCOS. Statistical analysis was performed with chi square and t-test, p-value<0.05 was con-
sidered as statistically significant. And receiver operating characteristic curve was used to find predictable clinical factors for endometrial dis-
ease and to decide the cuff off values. 
Results: In 117 women with PCOS, endometrial histologic profiles are as follows: proliferative phase in 90 women (76.9%), endometrial hyper-
plasia in 25 women (21.4%), and endometrial cancer in 2 women (1.7%). Of 25 women with endometrial hyperplasia, simple hyperplasia with-
out atypia, complex hyperplasia without atypia and complex hyperplasia with atypia were diagnosed in 15 (12.8%), 6 (5.1%), 4 (3.4%) women, 
respectively. Age and endometrial thickness were significantly related with endometrial disease, p=0.013 and p=0.001, respectively. At the 
cut off level of 25.5 years in age, sensitivity and specificity predicting for endometrial disease were 70.4% and 55.6%, respectively (p=0.023). At 
the cut off level of 8.5 mm in endometrial thickness, sensitivity and specificity were 77.8% and 56.7%, respectively (p=0.000). 
Conclusion: In women with PCOS, the incidence of endometrial hyperplasia and cancer were 21.4% and 1.7%. The age and endometrial thick-
ness may be used as clinical determining factors for endometrial biopsy.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine-
metabolic disorder in women of reproductive age with 5-10% of 
prevalence [1]. An international consensus group proposed that at 
least two out of three criteria have to be met in order to fit the diag-
nosis of PCOS. These criteria are oligo-anovulation (usually manifest-
ed as oligomenorrhea or amenorrhea), elevated levels of circulating 
androgens (hyperandrogenemia) or clinical manifestation of andro-
gen excess (hyperandrogenism), and polycystic ovaries as defined by 
ultrasonography. Also the syndrome can be diagnosed after the ex-
clusion of other known disorders, such as congenital adrenal hyper-
plasia, Cushing syndrome, and androgen producing tumors [2]. 
There are increasing evidences that the endocrinologic and metabol-
ic abnormalities in PCOS may have complex effects on the endome-
trium, contributing to the endometrial disorders observed in women 
with this syndrome [3]. In women with PCOS, the endometrium is 
exposed to the prolonged stimulatory effects of unopposed estro-
gen by chronic anovulation. And as the expression of androgen re-
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ceptor in the endometrium is up-regulated by estrogens and inhibit-
ed by progesterone, in women with PCOS elevated endometrial ex-
pression of the androgen receptor has been documented [4]. In ad-
dition, because endometrium is associated with insulin-like growth 
factor-1 (IGF-1) activation, decreased concentrations of sex hormone-
binding globulin (SHBG) and upregulation of endometrial aroma-
tase, hyperandrogenemia and hyperinsulinemia may further in-
crease the potential for neoplastic change in the endometrium 
[3,5,6]. Insulin resistance and hyperinsulinemia consequent to obesi-
ty may trigger or unmask the syndrome in genetically predisposed 
individuals. Therefore, in PCOS with prolonged unopposed estrogen, 
hyperinsulinemia, elevated free IGF-1 and androgens may further 
augment the mitogenic activity of endometrial cells, leading to ac-
celeration of hyperplasia and perhaps transformation to cancer [7,8].
However, it is still unclear whether all PCOS patients require an en-
dometrial biopsy to exclude endometrial disease and there are pre-
dictable clinical factors for the endometrial disease.
So, we performed this study to investigate the endometrial histolo-
gy and find the predictable clinical factors for the endometrial dis-
ease in women with PCOS.
Methods
This prospective study included 117 consecutive women with PCOS, 
defined as the 2003 Rotterdam criteria (2 out of 3): 1) oligo-anovula-
tion (menstrual cycle>37 day), 2) clinical or biochemical hyperan-
drogenism (total testosterone>2 SD), 3) ultrasound feature of poly-
cystic ovaries with 12 or more follicles of 2-9 mm diameter in each 
ovary. Clinical variables such as age, body weight and height were 
assessed in all subjects during a visit in the outpatient department. 
Body mass index (BMI) was calculated as weight (kg) divided by the 
square of height (m
2). A blood hormone test for LH, FSH, as well as E2 
and testosterone (T), was sampled on day 3 of the natural or induced 
menstrual cycle in PCOS patients. Blood hormone levels were asses-
sed using commercial kits, as follows; LH, FSH by immunoradiometric 
assay (IRMA; DIAsource SA, Nivelles, Belgium), E2 by radioimmunoas-
say (RIA; DIAsource SA) and serum total T by RIA (Radim SpA, Rome, 
Italy). Fasting and postprandial 2 hours glucose and insulin levels 
were evaluated by a 75 g oral glucose tolerance test using commer-
cial kits (Immunotech, Prague, Czech Republic) in order to assess in-
sulin resistance in all patients. The endometrial thickness was mea-
sured by vaginal or rectal route, as the widest distance from the re-
flective interface between the endometrium and myometrium of 
one side to the opposing side on a sagittal plane of the uterus [9], us-
ing a 5-MHz linear-array vaginal transducer (SSD 1000; Aloka, Tokyo, 
Japan). Because there were no clear clinical guidelines to suggest 
when an endometrial biopsy should be done [8], the endometrial bi-
opsy was performed in the all participants. All vaginal or rectal ultra-
sound assessments and endometrial biopsies were performed by 
one investigator to preclude the interobserver variation. The endo-
metrial tissues were sent for pathological diagnosis and we investi-
gated the incidence of each histologic pattern. Two main histologic 
types were classified as proliferative endometrium and diseased en-
dometrium. Simple, complex hyperplasia with or without cytologic 
atypia, or adenocarcinoma were included within the diseased endo-
metrium because of the relatively small number in each of the hyper-
plastic subcategories or adenocarcinoma. Then we compared clinical 
parameters, such as LH, FSH, E2, testosterone, fasting and 2 hours 
postprandial glucose and insulin, insulin resistance, BMI, age, endo-
metrial thickness and menstrual status between 2 groups to find the 
predictable clinical factor for endometrial disease in women with 
PCOS. In addition, a subgroup analysis was followed in some clinical 
parameters such as menstrual pattern (amenorrhea or oligomenor-
rhea), 2 hours gluocose (<140, 140-200, >200), 2 hours insulin (100-
150, 151-300, >300) and fasting glucose/insulin (<4.5, ≥4.5).
Clinical parameters between 2 groups were compared using a chi-
square test and the Student’s t-test. And receiver operating charac-
teristic (ROC) curve analysis was used to find the predictable clinical 
factor for endometrial disease and decide the cut off values. A p-val-
ue<0.05 was considered as statistically significant.
Results
In total of 117 PCOS patients, proliferative endometrium was found 
in 90 women with PCOS (76.9%), endometrial hyperplasia was diag-
nosed in 25 cases (21.4%) and endometrial adenocarcinoma was di-
agnosed in 2 cases (1.7%). Of the 25 cases of endometrial hyperpla-
sia, 15 (12.8%), 6 (5.1%), and 4 (3.4%) cases were classified as simple 
hyperplasia without cytologic atypia, complex hyperplasia without, 
and with atypia, respectively (Table 1). Two main histologic types 
were proliferative endometrium and endometrial disease. Of a all 
clinical parameters (age, BMI, LH, FSH, E2, testosterone, fasting glu-
cose, 2 hours postprandial glucose, fasting insulin, 2 hours postpran-
dial insulin, endometrial thickness), the mean age of the women with 
Table 1. Endometrial histologic profiles
Histologic profiles No. of patients (%)
Proliferative 90 (76.9)
Hyperplasia 25 (21.4)
   Simple without atypia 15 (12.8)
   Complex
      Without atypia 6 (5.1)
      With atypia 4 (3.4)
Adenocarcinoma 2 (1.7)
Total 117 (100)  doi: 10.5653/cerm.2011.38.1.42
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endometrial disease was significantly higher than that of women 
with proliferative endometrium (28.26±6.80 years vs. 25.10±5.37 
years; p=0.013). The mean thickness of the endometrium was signif-
icantly thicker in endometrial disease group, compared with the pro-
liferative endometrium group (13.56±6.76 mm vs. 8.78±3.32 mm; 
p=0.001). There were no significant differences in the remained clin-
ical parameters listed. The values of clinical parameters between 2 
endometrial histologic groups are summarized in Table 2. In the sub-
group analysis of the menstrual pattern, 2 hours glucose and insulin, 
and fasting glucose/insulin ratio, there was no statistically significant 
difference between 2 groups (Table 3). Only the endometrial thick-
ness and age were found to be significant predictors of endometrial 
disease in wo men with PCOS. 
The endometrial thickness and age were further evaluated in the 
ROC curve analysis. The areas under the ROC curves for age and en-
dometrial thickness were both greater than 0.5 (Figures 1, 2). The ar-
eas under the ROC curves for age and endometrial thickness were, 
respectively, 0.645 (95% confidence interval [CI], 0.518-0.771; p< 
0.05) and 0.734 (95% CI, 0.615-0.852; p<0.01). Also, using an endo-
metrial thickness of 8.5 mm as the cut off level predicting for endo-
metrial disease, the sensitivity and specificity would be 77.8% and 
56.7%, respectively; using an age of 25.5 years as the cut off level, the 
Table 2. Values of clinical parameters between endometrial histolog-
ic types
Clinical parameters
Groups
p-value Proliferative
(n=90)
Endometrial disease
(n=27)
Age (yr) 25.10±5.37 28.26±6.80 0.013
a
BMI (Kg/m
2) 24.78±5.29 25.09±6.14 0.800
LH (mIU/mL) 8.88±4.76 7.98±5.05 0.400
FSH (mIU/mL) 4.47±1.71 4.24±1.89 0.554
E2 (pg/mL) 61.46±35.36 91.95±81.19 0.068
Testosterone (ng/mL) 0.65±0.34 0.52±0.25 0.076
Fasting glucose (mg/dL) 89.60±18.63 92.63±16.59 0.449
2 hr glucose (mg/dL) 117.32±48.05 123.37±50.83 0.572
Fasting insulin (μU/mL) 10.43±8.04 23.76±69.29 0.074
2 hr insulin (μU/mL) 62.58±56.02 70.81±76.43 0.542
Endometrial thickness (mm) 8.78±3.32 13.56±6.76 0.001
a
Values are presented as mean±SD.
BMI, body mass index; LH, luteinizing hormone; FSH, follicle-stimulating hor-
mone; E2, estradiol.
ap<0.05.
Table 3. Distribution of patients according to category between en-
dometrial histologic types
Clinical parameters Category
Groups
p-
value Proliferative 
(n=90)
Endometrial 
disease 
(n=27)
Menstrual pattern Amenorrhea 24 (26.67) 7 (25.93) 0.939
Oligomenorrhea 66 (73.33) 20 (74.07)
2 hr glucose (mg/dL) <140 72 (80) 21 (77.78) 0.969
140-200 12 (13.33) 4 (14.81)
>200 6 (6.67) 2 (7.41)
2 hr insulin (μU/mL) 100-150 10 (58.82) 6 (85.71) 0.180
151-300 6 (35.29) 0 (0.00)
>300 1 (5.88) 1 (14.29)
Fasting glucose/insulin <4.5 9 (10) 3 (11.11) 1.000
≥4.5 81 (90) 24 (88.89)
Values are presented as number (%).
Figure 1. Receiver operating characteristic (ROC) curve for age. The 
closer the ROC plot is to the upper left corner, the higher the overall 
accuracy of the test. When the variable under study cannot distin-
guish between the two groups, the area under the ROC curve is 
equal to 0.5 (diagonal straight line).
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Figure 2. Receiver operating characteristic (ROC) curve for endome-
trial thickness.
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corresponding values would be 70.4% and 55.6%.
Discussion
PCOS is a complex disorder with metabolic and endocrine manifes-
tations and seems to have long term health consequences of the 
syndrome [10]. In addition to the diabetes, cardiovascular disease 
and breast cancer, the effect of the unopposed and uninterrupted 
estrogenic stimulation is to place the patient at considerable risk for 
endometrial cancer [5,10,11]. The known factors which increase the 
risk of developing endometrial hyperplasia and cancer are obesity, 
nulliparity, infertility, hypertension and diabetes [12]. Most of these 
factors are also known to be associated with PCOS [10]. Therefore, it 
is important to evaluate the endometrium and recognize the clinical 
factors that are likely to have affected on endometrial disease in wo-
men with PCOS. To our knowledge, this is likely to be the first study 
to investigate the endometrial histology and find the predictable 
clinical factors for endometrial disease in Korean women with PCOS. 
The incidence of endometrial disease in our study was 23.1% of wo-
men with PCOS and of these, 21.4% and 1.7% were endometrial hy-
perplasia and endometrial cancer, respectively. In another study [8], 
the endometrial hyperplasia was diagnosed in 35.7% of women with 
PCOS who were not receiving either contraceptive steroids or peri-
odic or monthly progestin withdrawal. In a long-term follow up study 
of women with PCOS based on ovarian wedge resection, the odds 
ratio for endometrial cancer was 5.3 (95% CI, 1.55-18.60) compared 
with control subjects [12]. In a larger study of 1,270 women with chro-
nic anovulation, the relative risk of endometrial cancer was identified 
to be 3.1 (95% CI, 1.1-7.3) and the risk was only significantly increa-
sed in the subgroup of overweight women [13]. Then, the question 
whether all PCOS patients require an endometrial biopsy to exclude 
endometrial disease remains unanswered and if so, predictable clini-
cal factors for endometrial disease are questionable. Many authors 
agree that in postmenopausal women with uterine bleeding, the en-
dometrial thickness on vaginal ultrasound assessment has been pos-
itively correlated with the presence of endometrial abnormalities, 
and curettage can be avoided if the endometrial thickness is less than 
4 mm [14,15]. In PCOS patients, unfortunately there are no clear clini-
cal guidelines to determine when the endometrial biopsy should be 
performed [8]. Cheung [8] demonstrated that in anovulatory, infer-
tile women with PCOS, endometrial thickness greater than 7 mm or 
intermenstrual interval of more than 3 months can be associated 
with endometrial hyperplasia and an endometrial biopsy would be 
recommended. Other authors propose that endometrial biopsy is in-
dicated when the clinical history suggests long-term unopposed es-
trogen exposure even when the endometrial thickness is normal (5-
12 mm), and that biopsy should be performed when endometrial 
thickness is greater than 12 mm even when clinical suspicion of dis-
ease is low [6]. In our study, although this study has a limitation that 
has been not shown an intermenstrual interval or the duration of ex-
posure to unopposed estrogen, the endometrial thickness and age 
were positively correlated with the presence of endometrial disease 
in women with PCOS. Also, our study showed that in women with 
PCOS, endometrial thickness more than 8.5 mm or age more than 
25.5 years could be associated with the endometrial disease.
In conclusion, it seems that the endometrium in women with PCOS 
is different from it of healthy women in the endocrinological aspect, 
and is consistent with a higher incidence of hyperplasia and cancer 
[16]. Theoretically, there are many clinical factors developing endo-
metrial hyperplasia or cancer, but an endometrial biopsy to exclude 
endometrial disease should be considered according to the clinical 
status. And also, the results of this study suggest that the age and en-
dometrial thickness may be used as clinical determining factor for 
endometrial biopsy.
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